Since targeting T/E fusion alone cannot stop tumor growth completely, in combination of other NF-kB inhibitor and/or blocking CCL2 pathway may be an efficacious approach for this major group of PCas carrying T/E fusion. This evidence concerns the gene CCL2 and neoplasm.